Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Flow Cytometry | 6 | 2020 | 2393 | 1.49 | Why? |
| Anti-HIV Agents | 4 | 2021 | 2209 | 0.73 | Why? |
| Hemangioblastoma | 1 | 2017 | 4 | 0.73 | Why? |
| Immunoglobulin Isotypes | 1 | 2020 | 308 | 0.73 | Why? |
| Medical Laboratory Personnel | 1 | 2020 | 254 | 0.70 | Why? |
| Immunologic Techniques | 1 | 2017 | 71 | 0.69 | Why? |
| Neoplastic Cells, Circulating | 1 | 2017 | 68 | 0.67 | Why? |
| Staining and Labeling | 1 | 2018 | 169 | 0.66 | Why? |
| Energy Metabolism | 1 | 2020 | 451 | 0.62 | Why? |
| Virus Latency | 1 | 2018 | 251 | 0.61 | Why? |
| DNA | 2 | 2018 | 778 | 0.57 | Why? |
| RNA | 2 | 2017 | 1278 | 0.56 | Why? |
| Microscopy | 1 | 2018 | 414 | 0.55 | Why? |
| HIV Infections | 9 | 2018 | 11620 | 0.53 | Why? |
| Mitochondria | 1 | 2020 | 857 | 0.51 | Why? |
| T-Lymphocyte Subsets | 2 | 2020 | 1387 | 0.50 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.50 | Why? |
| CD8-Positive T-Lymphocytes | 6 | 2021 | 5837 | 0.50 | Why? |
| Monocytes | 2 | 2021 | 2978 | 0.44 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2018 | 309 | 0.41 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2020 | 4545 | 0.41 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.38 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.36 | Why? |
| Cytokines | 5 | 2021 | 15010 | 0.33 | Why? |
| Geriatrics | 1 | 2017 | 947 | 0.33 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.32 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 15 | 0.30 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.29 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.27 | Why? |
| Adipocytes | 1 | 2005 | 173 | 0.26 | Why? |
| Aging | 2 | 2017 | 3581 | 0.26 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.26 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.26 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.24 | Why? |
| Lymphocyte Activation | 3 | 2021 | 2742 | 0.23 | Why? |
| Inflammation | 5 | 2021 | 13255 | 0.23 | Why? |
| Primary Cell Culture | 2 | 2020 | 501 | 0.22 | Why? |
| Cell Proliferation | 2 | 2020 | 1973 | 0.22 | Why? |
| Cell Size | 1 | 2021 | 106 | 0.22 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.22 | Why? |
| Transistors, Electronic | 2 | 2021 | 48 | 0.22 | Why? |
| Ki-67 Antigen | 1 | 2021 | 139 | 0.22 | Why? |
| Palatine Tonsil | 1 | 2021 | 127 | 0.21 | Why? |
| CD4-CD8 Ratio | 2 | 2018 | 235 | 0.20 | Why? |
| Cobicistat | 1 | 2021 | 172 | 0.20 | Why? |
| Cell Cycle | 1 | 2021 | 329 | 0.20 | Why? |
| Tonsillectomy | 1 | 2021 | 115 | 0.20 | Why? |
| Immunologic Memory | 3 | 2021 | 3362 | 0.20 | Why? |
| Heterochromatin | 1 | 2018 | 5 | 0.19 | Why? |
| Cell Separation | 2 | 2017 | 270 | 0.19 | Why? |
| Cell Death | 1 | 2021 | 536 | 0.19 | Why? |
| Natural Killer T-Cells | 2 | 2017 | 191 | 0.18 | Why? |
| Lymphocyte Count | 2 | 2020 | 4758 | 0.18 | Why? |
| Herpesvirus 1, Human | 1 | 2021 | 286 | 0.18 | Why? |
| DNA Topoisomerases, Type I | 1 | 2018 | 86 | 0.18 | Why? |
| Fas Ligand Protein | 1 | 2017 | 69 | 0.18 | Why? |
| Herpes Simplex | 1 | 2021 | 272 | 0.17 | Why? |
| Famous Persons | 1 | 2018 | 74 | 0.17 | Why? |
| Liver Failure, Acute | 1 | 2021 | 279 | 0.17 | Why? |
| fas Receptor | 1 | 2017 | 85 | 0.17 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.17 | Why? |
| Darunavir | 1 | 2021 | 477 | 0.17 | Why? |
| Surface-Active Agents | 1 | 2020 | 267 | 0.17 | Why? |
| Cellular Senescence | 1 | 2020 | 326 | 0.16 | Why? |
| Biomarkers | 8 | 2021 | 23361 | 0.16 | Why? |
| Transcription, Genetic | 2 | 2018 | 1326 | 0.16 | Why? |
| Protective Clothing | 1 | 2020 | 468 | 0.16 | Why? |
| Immunodominant Epitopes | 1 | 2021 | 813 | 0.16 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.15 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.15 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.15 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.15 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.15 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.15 | Why? |
| Cholangiocarcinoma | 1 | 2017 | 186 | 0.14 | Why? |
| Th17 Cells | 1 | 2020 | 657 | 0.14 | Why? |
| Biosensing Techniques | 2 | 2021 | 2116 | 0.14 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2017 | 170 | 0.14 | Why? |
| Genome, Human | 1 | 2018 | 400 | 0.14 | Why? |
| Poliomyelitis | 1 | 2018 | 263 | 0.14 | Why? |
| Chemokines | 1 | 2020 | 1095 | 0.14 | Why? |
| Respiratory Therapy | 1 | 2021 | 918 | 0.14 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.13 | Why? |
| Fluorescent Dyes | 1 | 2018 | 536 | 0.13 | Why? |
| Organ Dysfunction Scores | 1 | 2020 | 1475 | 0.13 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.13 | Why? |
| Humans | 42 | 2021 | 930598 | 0.13 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.13 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.13 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 398 | 0.12 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.12 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.12 | Why? |
| Italy | 7 | 2021 | 38444 | 0.12 | Why? |
| False Positive Reactions | 1 | 2017 | 1338 | 0.12 | Why? |
| Lung | 1 | 2020 | 31049 | 0.11 | Why? |
| Aged | 14 | 2021 | 215776 | 0.11 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.11 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.10 | Why? |
| Adult | 13 | 2021 | 244371 | 0.10 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.10 | Why? |
| DNA, Viral | 2 | 2017 | 2521 | 0.10 | Why? |
| Female | 18 | 2021 | 380317 | 0.10 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.09 | Why? |
| Disease Susceptibility | 2 | 2019 | 4002 | 0.09 | Why? |
| Male | 18 | 2021 | 367725 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| C-Reactive Protein | 2 | 2021 | 7972 | 0.08 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.08 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.08 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2021 | 1969 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2016 | 2483 | 0.08 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.08 | Why? |
| Software | 1 | 2017 | 2501 | 0.07 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.07 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.07 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.07 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| DNA, Mitochondrial | 1 | 2005 | 163 | 0.06 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Electrolytes | 1 | 2021 | 103 | 0.05 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.05 | Why? |
| Multiple Sclerosis | 1 | 2017 | 2600 | 0.05 | Why? |
| Instillation, Drug | 1 | 2020 | 28 | 0.05 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.05 | Why? |
| Immunomodulation | 2 | 2021 | 1472 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Lamin Type B | 1 | 2018 | 5 | 0.05 | Why? |
| Resting Phase, Cell Cycle | 1 | 2018 | 9 | 0.05 | Why? |
| Markov Chains | 1 | 2021 | 502 | 0.05 | Why? |
| RNA Polymerase II | 1 | 2018 | 29 | 0.05 | Why? |
| Chromatin Immunoprecipitation | 1 | 2018 | 53 | 0.05 | Why? |
| G1 Phase Cell Cycle Checkpoints | 1 | 2018 | 26 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Apoptosis | 2 | 2021 | 2335 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2019 | 11041 | 0.05 | Why? |
| Molecular Sequence Data | 1 | 2005 | 3198 | 0.05 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
| Poliovirus Vaccines | 1 | 2018 | 85 | 0.05 | Why? |
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2017 | 7 | 0.05 | Why? |
| Sampling Studies | 1 | 2020 | 386 | 0.05 | Why? |
| Epitopes, T-Lymphocyte | 2 | 2021 | 2262 | 0.04 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.04 | Why? |
| DNA Replication | 1 | 2018 | 121 | 0.04 | Why? |
| Polyproteins | 1 | 2021 | 814 | 0.04 | Why? |
| Electric Capacitance | 1 | 2016 | 3 | 0.04 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.04 | Why? |
| Endothelium | 1 | 2021 | 460 | 0.04 | Why? |
| Caspases | 1 | 2017 | 156 | 0.04 | Why? |
| Gene Silencing | 1 | 2018 | 213 | 0.04 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Semiconductors | 1 | 2016 | 25 | 0.04 | Why? |
| Bile Ducts, Intrahepatic | 1 | 2017 | 68 | 0.04 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| HIV Envelope Protein gp41 | 1 | 2018 | 153 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2020 | 893 | 0.04 | Why? |
| Animals | 4 | 2021 | 78931 | 0.04 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.04 | Why? |
| Base Sequence | 1 | 2005 | 3581 | 0.04 | Why? |
| Adaptive Immunity | 2 | 2019 | 2585 | 0.04 | Why? |
| Histocompatibility Antigens Class I | 1 | 2021 | 624 | 0.04 | Why? |
| Russia | 1 | 2020 | 989 | 0.04 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.04 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2018 | 385 | 0.04 | Why? |
| Histones | 1 | 2018 | 371 | 0.04 | Why? |
| Immunity, Innate | 3 | 2019 | 6570 | 0.04 | Why? |
| Fibrinogen | 1 | 2021 | 1048 | 0.04 | Why? |
| Alleles | 1 | 2021 | 1557 | 0.04 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.04 | Why? |
| Bile Duct Neoplasms | 1 | 2017 | 172 | 0.04 | Why? |
| Nucleic Acid Conformation | 1 | 2018 | 621 | 0.04 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.03 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.03 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 552 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.03 | Why? |
| Lab-On-A-Chip Devices | 1 | 2016 | 411 | 0.03 | Why? |
| Thermodynamics | 1 | 2016 | 873 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Ischemia | 1 | 2020 | 901 | 0.03 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Immune System | 1 | 2019 | 1479 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.02 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.02 | Why? |
| Equipment Design | 1 | 2016 | 3095 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Models, Statistical | 1 | 2020 | 5312 | 0.02 | Why? |
| Virus Internalization | 1 | 2021 | 7921 | 0.01 | Why? |
| Viral Proteins | 1 | 2021 | 7370 | 0.01 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.01 | Why? |
| Mice | 1 | 2021 | 21357 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |